Investor Presentation 1H FY24 and Market Update
Filed with ASX · · 20 pages · English
Become a leading life science company in Asia- Pacific, improving the quality of life and human health by accelerating innovation to market. Company Highlights High Demand Products Scientifically formulated products developed for fast-growing consumer markets. Established Client Base Established relationships with leading distributors in Asia-Pacific to supplement digital strategy. Omnichannel Mar
EZZ Life Science Holdings Ltd. on 6ix
In the deck
Story so far
Earlier from EZZ Life Science
- FY23 (unaudited) Results Presentation
- EZZ announces Major Distribution Agreement with HIC
- EZZ launches Amazon online store and new product releases
- Updated Appendix 4C
- FY22 Results Presentation
Later from EZZ Life Science
- EZZ Completes Private Placement with Strategic Investor
- Half Year Interim Dividend
- EZZ Secures Major Sales Agreement with Pinehills (HK) Ltd
- EZZ Targets US Expansion Receives Product Approvals from FDA
- EZZ Expands Portfolio with 4 Functional Food Products
Follow EZZ Life Science into a list and get an email when it puts out news.
Follow EZZ Life Science